The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $75.03

Today's change-0.09 -0.12%
Updated July 27 4:01 PM EDT. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $75.03

Today's change-0.09 -0.12%
Updated July 27 4:01 PM EDT. Delayed by at least 15 minutes.

Charles River Laboratories International Inc down (U.S.)$0.09

Charles River Laboratories International Inc closed lower Monday, dropping (U.S.)$0.09 or 0.12% to (U.S.)$75.03. Shares have lost 1.05% over the last five days, but have gained 17.90% over the last year to date. This security has outperformed the S&P 500 by 34.82% during the last year.

Key company metrics

  • Open(U.S.) $74.55
  • Previous close(U.S.) $75.12
  • High(U.S.) $75.41
  • Low(U.S.) $74.15
  • Bid / Ask-- / --
  • YTD % change+17.90%
  • Volume365,268
  • Average volume (10-day)413,923
  • Average volume (1-month)540,729
  • Average volume (3-month)444,694
  • 52-week range(U.S.) $52.39 to (U.S.) $84.69
  • Beta1.44
  • Trailing P/E27.95×
  • P/E 1 year forward20.61×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.68
Updated July 27 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.78%

Based on its net profit margin of 9.78%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.30%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 28, 201503/28/2015Dec 27, 201412/27/2014Sep 27, 201409/27/2014Jun 28, 201406/28/2014
Revenue320330328341
Total other revenue--------
Total revenue320330328341
Gross profit120120118126
Total cost of revenue201210209216
Total operating expense277289281290
Selling / general / administrative71686468
Research & development--------
Depreciation / amortization5787
Interest expense (income), net operating--------
Unusual expense (income)14----
Other operating expenses, total--------
Operating income43414651
Interest income (expense), net non-operating-3-3-3-3
Gain (loss) on sale of assets--------
Other--------
Income before tax32404451
Income after tax32293236
Income tax, total0121214
Net income32273235
Total adjustments to net income--------
Net income before extra. items32283236
Minority interest0-10-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items32283236
Inc. avail. to common incl. extra. items32273235
Diluted net income32273235
Dilution adjustment000--
Diluted weighted average shares48484748
Diluted EPS excluding extraordinary itemsvalue per share0.660.590.680.75
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.651.340.690.80